Literature DB >> 3812484

Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting.

D Fabbro, R J Desnick, G A Grabowski.   

Abstract

The genetic heterogeneity of Gaucher disease subtypes and variants was investigated by immunoblotting of fibroblast extracts. For these studies polyclonal and monoclonal antibodies were raised to acid beta-glucosidase preparations containing a single N-terminal amino acid sequence that was colinear with that encoded by the beta-Glc cDNAs. Three forms (Mr approximately equal to 67,000, 64,000-61,000, and 58,000) of cross-reacting immunologic material (CRIM) were observed in control individuals. Decreased amounts of the same CRIM forms were detected in most type 1 Gaucher disease patients, but single CRIM forms of variable molecular weight were observed in several non-Jewish type 1 variants. One or two CRIM forms of variable molecular weight were found in neuronopathic (type 2 and type 3) patients. The amount of CRIM was severely decreased in the majority of the type 2 and type 3 patients; one American black type 2 patient was CRIM negative. With this one exception, one CRIM form was detected in the cell-free culture media from all normal or Gaucher disease fibroblasts that had an Mr approximately 2,000 greater than the highest respective intracellular molecular-weight form. All intra- or extracellular CRIM forms were reduced to a single form after deglycosylation with N-Glycanase. In addition, the radioactivity from [3H]Br-conduritol B epoxide, a specific covalent inhibitor of beta-Glc, localized to the CRIM forms of beta-Glc on immunoblots. These results indicate that all subtypes and variants of Gaucher disease result from mutations that alter the stability and/or processing of beta-Glc. Furthermore, the heterogeneity of the CRIM patterns within and among the variants of Gaucher disease cause the diagnostic usefulness of immunoblotting to be restricted to those families in which the phenotype has been well established.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3812484      PMCID: PMC1684010     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  29 in total

1.  A case of juvenile Gaucher's disease with intraneuronal lipid storage.

Authors:  A F MALONEY; J N CUMINGS
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-08       Impact factor: 10.154

2.  Molecular basis for the alpha1-protease inhibitor deficiency.

Authors:  S K Chan; D C Rees
Journal:  Nature       Date:  1975-05-15       Impact factor: 49.962

3.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

4.  Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA.

Authors:  J Sorge; C West; B Westwood; E Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Biosynthesis of the lysosomal enzyme glucocerebrosidase.

Authors:  A H Erickson; E I Ginns; J A Barranger
Journal:  J Biol Chem       Date:  1985-11-15       Impact factor: 5.157

7.  Gaucher disease: the effects of phosphatidylserine on glucocerebrosidase from normal and Gaucher fibroblasts.

Authors:  F Y Choy
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

8.  Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine.

Authors:  G A Grabowski; T Dinur; K M Osiecki; J R Kruse; G Legler; S Gatt
Journal:  Am J Hum Genet       Date:  1985-05       Impact factor: 11.025

9.  Genetic heterogeneity in Gaucher disease: physicokinetic and immunologic studies of the residual enzyme in cultured fibroblasts from non-neuronopathic and neuronopathic patients.

Authors:  G A Grabowski; J Goldblatt; T Dinur; J Kruse; L Svennerholm; S Gatt; R J Desnick
Journal:  Am J Med Genet       Date:  1985-07

10.  Non-neuropathic Gaucher disease presenting in infancy.

Authors:  P Hodson; J Goldblatt; P Beighton
Journal:  Arch Dis Child       Date:  1979-09       Impact factor: 3.791

View more
  23 in total

1.  Participation of asparagine 370 and glutamine 235 in the catalysis by acid beta-glucosidase: the enzyme deficient in Gaucher disease.

Authors:  Benjamin Liou; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2009-02-13       Impact factor: 4.797

2.  The clinical, molecular, and pathological characterisation of a family with two cases of lethal perinatal type 2 Gaucher disease.

Authors:  E Sidransky; N Tayebi; B K Stubblefield; W Eliason; A Klineburgess; G P Pizzolato; J N Cox; J Porta; A Bottani; C D DeLozier-Blanchet
Journal:  J Med Genet       Date:  1996-02       Impact factor: 6.318

3.  Molecular analysis of Japanese Gaucher disease.

Authors:  T Ohashi; Y Eto
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

4.  Comparative study on glucocerebrosidase in spleens from patients with Gaucher disease.

Authors:  J M Aerts; W E Donker-Koopman; S Brul; S Van Weely; M C Sa Miranda; J A Barranger; J M Tager; A W Schram
Journal:  Biochem J       Date:  1990-07-01       Impact factor: 3.857

5.  Generation of polyclonal antibodies against recombinant human glucocerebrosidase produced in Escherichia coli.

Authors:  Juliana Branco Novo; Maria Leonor Sarno Oliveira; Geraldo Santana Magalhães; Ligia Morganti; Isaías Raw; Paulo Lee Ho
Journal:  Mol Biotechnol       Date:  2010-11       Impact factor: 2.695

6.  Complex alleles of the acid beta-glucosidase gene in Gaucher disease.

Authors:  T Latham; G A Grabowski; B D Theophilus; F I Smith
Journal:  Am J Hum Genet       Date:  1990-07       Impact factor: 11.025

7.  Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model.

Authors:  You-Hai Xu; Ying Sun; Sonya Barnes; Gregory A Grabowski
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

8.  Gaucher disease: heterologous expression of two alleles associated with neuronopathic phenotypes.

Authors:  M E Grace; A Berg; G S He; L Goldberg; M Horowitz; G A Grabowski
Journal:  Am J Hum Genet       Date:  1991-09       Impact factor: 11.025

9.  Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase.

Authors:  S S Kang; J Zhou; P W Wong; J Kowalisyn; G Strokosch
Journal:  Am J Hum Genet       Date:  1988-10       Impact factor: 11.025

10.  Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.

Authors:  You-Hai Xu; Brian Quinn; David Witte; Gregory A Grabowski
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.